FDMT

4D Molecular Therapeutics, Inc. is a cutting-edge clinical-stage gene therapy company based in Emeryville, California, specializing in the development of innovative therapeutics through its proprietary adeno-associated virus (AAV) vector platform. Focused on addressing significant unmet medical needs in ophthalmology, neurology, and rare diseases, the company is committed to transforming patient outcomes with its advanced gene therapies. With a robust pipeline and strategic partnerships, 4D Molecular Therapeutics is well-positioned to lead the biotherapeutics sector and drive the commercialization of novel treatments, enhancing its standing as a key player in the biotechnology landscape.